Compare BioNTech SE - ADR (BNTX) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Valero Energy Corporation — how do they compare? BioNTech SE - ADR trades at $91.5 (market cap $22.86B), while Valero Energy Corporation trades at $292.15 (market cap $89.50B). The key difference: Valero Energy Corporation is far larger — about 3.9× BioNTech SE - ADR's market cap, and Valero Energy Corporation pays a 1.59% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | VLO | |
|---|---|---|
Market Cap | $22.86B | $89.50B |
Sector | Health | Energy |
52-Week High | $119.34 | $301.43 |
52-Week Low | $83.89 | $131.77 |
Enterprise Value | $6.53B | $95.26B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Valero Energy (VLO) trades at $295.79, up 5.38% in the last session, reflecting strong momentum amid bullish technical signals and positive earnings surprises. The stock's valuation metrics, including a P/E of 20.5 and P/S of 0.69, appear reasonable relative to historical levels, while profitability remains solid with a 17.72% ROE. Recent news highlights VLO's exposure to elevated refining margins and strong fuel demand, particularly benefiting its Gulf Coast operations.
The outlook for VLO is supported by robust refining fundamentals and a favorable analyst consensus, though risks include volatile energy markets and declining revenue trends. Upside potential exists if the company continues to exceed earnings expectations and capitalizes on tight product supplies, but investors should monitor margin pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
